Shots: Mergers and Acquisitions are among the predominant elements of the Biopharma Industry. Owing to the repercussions of the Russia-Ukraine war and the ongoing COVID-19 pandemic, the IPOs, public markets, anti-trust law reforms by the US FTC, and M&As among others were relatively low in the biopharma sector in the year 2022 In the year…
Shots:The fourth quarter of 2022 highlights approvals, multiple clinical trial results, and numerous deals. There are major alliances in this quarter which include Johnson & Johnson acquired Abiomed for ~$16.6B, Takeda entered into an agreement to acquire NDI-034858 from Nimbus Therapeutics for ~$6BIn the fourth quarter of the year, BeiGene’s Brukinsa received EC’s…

